



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – November 6, 2018

MEDraysintell anticipates increasing M&A activities in nuclear medicine

Some US\$10 billion in M&A transactions during the past four years

With the recent announcement by Novartis to acquire Endocyte (October 2018), interest from the conventional pharmaceutical industry towards radiopharmaceuticals and in particular radiotherapeutics and radiotheranostics is clearly growing, as foreseen few years ago by MEDraysintell.

Three major acquisitions involved the conventional pharmaceutical industry over the past four years: in 2014, Bayer acquired Algeta ASA and its major drug for end-stage prostate cancer treatment ²²³Ra-Xofigo for about NOK 17.6 billion (US\$ 2.9 billion), while Novartis took over Advanced Accelerator Applications (AAA) and its Neuro Endocrine Tumor treatment ¹⁷⁷Lu-Lutathera in January 2018 for a total value of US\$ 3.9 billion; additionally Novartis announced in October 2018 the acquisition of the company Endocyte developing the prostate cancer drug ¹⁷⁷Lu-PSMA-617 for a total value of US\$ 2.1 billion, this transaction is expected to be completed in the first half of 2019. Ipsen Pharma acquired in May 2015 the German company OctreoPharm Sciences GmbH, for a total of EUR 50 million (about US\$ 55 million) and one year later a large part of the radiopharmaceutical pipeline of the German company 3B Pharmaceuticals GmbH. Also Sun Pharmaceutical Industries acquired Pharmeducence in July 2014 for an undisclosed amount.

Within the radiopharmaceutical industry other mergers showed consolidation of this industry: IBA Molecular acquired the Nuclear Medicine business of Mallinckrodt in January 2017 for a total of about US\$ 690 million and Jubilant Draximage acquired the Triad Isotopes radiopharmacy network in May 2017, while Sofie Biosciences took over Zevacor Pharma in May 2017.

There are great chances that additional M&A will take place within the next 12 months, while at the same time the conventional pharmaceutical industry is now looking for new opportunities in early stage research programs in this area. MEDraysintell anticipates that the global market will reach US\$ 5.9 billion in 2019 and it is now expected that radiotherapeutics will represent more than 60% of the US\$ 26 billion nuclear medicine market by 2030.

Most of the development of new radiopharmaceuticals is performed by new medium-sized radiopharmaceuticals companies and conventional pharmaceutical corporations, which are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018. The MEDraysintell Nuclear Medicine report has become the sole trusted source of intelligence in this industry and this fifth edition will prove once again to be the best advising tool for the pharmaceutical and radiopharmaceutical industry, investment organizations, international consulting firms, R&D laboratories to understand the market, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A) in this field.

Detailed table of contents and sample pages available upon request at peg@medraysintell.com



About MEDraysintell

Strategic intelligence for the radiation healthcare

Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 2,200 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 70 years of experience in radiation healthcare. www.medraysintell.com

Contact

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
e-Mail: peg@medraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
e-Mail: rz@medraysintell.com
Mobile: +33 6 82 80 06 00